[email protected]
CDI - Contrive Datum Insights
Medical Devices

Remote Patient Monitoring MarketSize, Share & Industry Analysis, 2026-2034By Product TypeBy ComponentBy ApplicationBy End UserBy Connectivity TechnologyBy WearabilityBy Deployment ModeBy Care ModelBy Patient Age GroupBy Sales Channel

Full title & scope — all 10 axes with their segments

Remote Patient Monitoring Market Size, Share & Industry Analysis, By Product Type (Vital Signs Monitors, Glucose Monitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Multi-parameter Monitors, Fetal and Neonatal Monitors, Neurological Monitors, Weight and Body Composition Scales), By Component (Devices, Software and Platforms, Services), By Application (Cardiovascular Diseases, Diabetes, Respiratory Diseases, Neurological Disorders, Cancer, Maternal and Fetal Health, Post-acute and Post-operative Care, Other Chronic Conditions), By End User (Home Care Settings, Hospitals and Clinics, Ambulatory Care Centers, Assisted Living and Long-term Care Facilities, Rehabilitation Centers, Payers and Care Management Organizations), By Connectivity Technology (Bluetooth, Wi-Fi, Cellular, Wired and Hub-based, Other Wireless Protocols), By Wearability (Wearable, Handheld, Tabletop and Bedside, Implantable and Ingestible), By Deployment Mode (Cloud-based, On-premise, Hybrid), By Care Model (Real-time Monitoring, Store-and-forward Monitoring, Hospital-at-home, Chronic Care Management, Principal Care Management), By Patient Age Group (Geriatric, Adult, Pediatric, Neonatal), By Sales Channel (Direct to Providers, Distributors and Wholesalers, Retail and Pharmacies, Online and E-commerce, Payer-sponsored Programs), and Regional Forecast, 2026-2034

Last Updated: Oct 30, 2026Format: PDFReport ID: CDI-248812
Summary

Market outlook, key takeaways, drivers and challenges for the report period.

Historical period
2020-2024
Base year
2025
Forecast period
2026-2034
CAGR
11.3%
Market size trend
20202025 base year2034
Global market size
2025 · baseUSD 26 Billion
2026USD 30 Billion
2034 · forecastUSD 70.8 Billion
Leading region, 2025
North America · 41%
Leading region
North America leads with 41% of global revenue through 2034
Segmentation
  1. 01By Product TypeVital Signs Monitors · Glucose Monitoring Devices · Cardiac Monitoring Devices
  2. 02By ComponentDevices · Software and Platforms · Services
  3. 03By ApplicationCardiovascular Diseases · Diabetes · Respiratory Diseases
  4. 04By End UserHome Care Settings · Hospitals and Clinics · Ambulatory Care Centers
  5. 05By Connectivity TechnologyBluetooth · Wi-Fi · Cellular
  6. 06By WearabilityWearable · Handheld · Tabletop and Bedside
  7. 07By Deployment ModeCloud-based · On-premise · Hybrid
  8. 08By Care ModelReal-time Monitoring · Store-and-forward Monitoring · Hospital-at-home
  9. 09By Patient Age GroupGeriatric · Adult · Pediatric
  10. 10By Sales ChannelDirect to Providers · Distributors and Wholesalers · Retail and Pharmacies
  11. 11By Region
Overview

Market Analysis & Outlook

Remote patient monitoring covers devices, software platforms and services that capture a patient's physiological data outside a clinical setting and send it to a care team for review and action. The category includes vital sign monitors, glucose and cardiac sensors, wearables and implantables, the cloud or on-premise software that collects and analyses the readings, and the enrolment and clinical support services around them. Buyers include hospitals and health systems, clinics, home care and assisted living operators, payers and care management organisations, and consumers who purchase connected devices directly.

Between 2025 and 2034 the global remote patient monitoring market moves from USD 26 billion to USD 70.8 billion, compounding at 11.3% a year. Fifteen years are covered in all, taking in USD 11.5 billion in 2020, USD 22.2 billion in 2024, USD 30 billion in 2026 and USD 48.6 billion in 2030.

On the product type axis, growth rates run from 9.07% for Multi-parameter Monitors up to 16.34% for Neurological Monitors. Vital Signs Monitors carries the volume: USD 6.24 billion and 24% of revenue in 2025, USD 14.16 billion and 20% in 2034. The lines gaining share are Glucose Monitoring Devices, Cardiac Monitoring Devices and Neurological Monitors. Vital Signs Monitors, Respiratory Monitoring Devices, Multi-parameter Monitors, Fetal and Neonatal Monitors and Weight and Body Composition Scales lose share without losing revenue.

By component, Devices accounts for 52% of 2025 revenue at USD 13.52 billion, reaching USD 29.736 billion and 42% by 2034. Software and Platforms grows faster at 14.94% against 9.16%, moving from 28% of revenue to 36% by 2034. This axis divides the same revenue as the product type split instead of adding to it, so the two are read together and never summed.

Behind these figures sit five regions, eight product type lines and ten segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the same applies to the segment, regional and country breakdowns drawn from it.

Market Size, 2020–2034

USD Billion
Base year 2025
USD 26 Billion
Forecast 2034
USD 70.8 Billion
CAGR 2025–2034
11.3%
ActualForecast
80
60
40
20
0
11.5
13.6
16
18.9
22.2
26
30
34.2
38.7
43.5
48.6
53.9
59.4
65
70.8
Forecast →
2020
2022
2024
2026
2028
2030
2032
2034

Revenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.

Analysis

Key Takeaways

  • Revenue grows from USD 26 billion in 2025 to USD 70.8 billion in 2034, a compound annual rate of 11.3%, having reached USD 22.2 billion in 2024 from USD 11.5 billion in 2020.
  • 24% of 2025 revenue sits in Vital Signs Monitors (USD 6.24 billion) and it remains the largest product type line in 2034 at USD 14.16 billion and 20%.
  • Neurological Monitors is the fastest-growing line at 16.34%, lifting its share from 4% in 2025 to 6% in 2034 and its revenue from USD 1.04 billion to USD 4.248 billion.
  • Scenario range for 2034 runs from USD 59.4 billion in the bear case to USD 80.6 billion in the bull case, against a base-case USD 70.8 billion, the spread a plan built on this forecast has to absorb.
  • Within North America, the United States is the worked country example, at USD 9.4 billion in 2025; 89.27% of regional revenue in the base year, and USD 22.1 billion by 2034.
  • Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region, not as a single blended series.
Analysis

Revenue Share, By product type

Base year 2025

Vital Signs Monitors leads with 24.0% of product type segment revenue.

24%
Vital Signs Monitors
Vital Signs Monitors
24.0%
Cardiac Monitoring Devices
22.0%
Glucose Monitoring Devices
20.0%
Multi-parameter Monitors
12.0%
Respiratory Monitoring Devices
8.0%
Weight and Body Composition Scales
6.0%
Other (2)
8.0%

Share of product type segment revenue, most recent base year. The 2 smallest segments are grouped as Other.

Three things move over 2026-2034, and they are worth separating: the product type mix, the regional balance, and the 11.3% compounding underneath both.

The direction of the market is not in question in any of the three. Each line and each region grows in revenue terms; what separates them is which takes the larger part of the growth.

The product type mix tilts toward Neurological Monitors. Between 2026 and 2034, 16.34% growth in Neurological Monitors against 9.07% in Multi-parameter Monitors pulls the product type mix apart. Neurological Monitors takes its share of revenue from 4% to 6% while Multi-parameter Monitors gives up ground, from 12% to 10%. Neither contracts: USD 1.04 billion becomes USD 4.248 billion, USD 3.12 billion becomes USD 7.08 billion. What the spread decides is which of them a supplier's revenue is exposed to.

Regional shares hold while every regional total climbs. Nothing in the regional split changes hands over the forecast period, which turns regional strategy into a capacity question, not a competitive one.

A continuation, not an inflection. Fifteen years of revenue run USD 11.5 billion in 2020, USD 22.2 billion in 2024, USD 26 billion in 2025, USD 30 billion in 2026, USD 48.6 billion in 2030 and USD 70.8 billion in 2034. Against 17.7% through the historical period, the 11.3% forecast rate is a continuation; no year in the series interrupts it. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the product type and regional axes, not by the headline rate.

Analysis

Market Growth Factors

Neurological Monitors adds the most incremental growth

Market Drivers

3
  • 01
    Neurological Monitors adds the most incremental growth

    16.34% growth in Neurological Monitors, against 11.3% for the market as a whole, moves it from USD 1.04 billion and 4% of revenue in 2025 to USD 4.248 billion and 6% in 2034. The market's overall 11.3% depends on that rate holding: at the 9.07% recorded by Multi-parameter Monitors, the same revenue base would compound to a materially smaller 2034 total. That makes position on the product type axis a growth decision, not a product one.

  • 02
    Regional weight, not regional count

    Together the two account for the majority of both the 2025 base and the revenue added by 2034, which is why a regional plan treating all five regions at equal weight misreads where the growth actually lands.

  • 03
    A demonstrated trajectory, not a projected turnaround

    The historical period compounded at 17.7%; USD 11.5 billion in 2020, USD 22.2 billion in 2024 and USD 26 billion in 2025. From there the forecast carries 11.3% through to USD 70.8 billion in 2034. Because the growth is already in the record and not only in the projection, the rate is held flat across the forecast instead of ramped, and the risk in the number sits in the mix assumptions, not in whether the market grows at all.

Growth drivers

#Growth driverImpactGross contribution (Billion)2026-282029-312032-34
1Rising chronic disease burden and ageing populationsHigh+15HighHighMedium
2Reimbursement for remote monitoring and the move to value-based careHigh+11.5HighHighMedium
3Adoption of wearable and cellular-connected devicesMedium-High+9HighMediumMedium
4Hospital-at-home and early discharge programsMedium-High+7.5MediumHighHigh
5Analytics and automated alerting built into monitoring platformsMedium+4.5MediumMediumHigh
6OthersLow+3.8LowLowLow
Total+51.3

Restraints

#RestraintImpactEstimated reduction (Billion)2026-282029-312032-34
1Reimbursement complexity and data privacy compliance costsMedium-High−3.6MediumMediumLow
2Clinician workload and alert fatigueMedium−2MediumMediumLow
3Device price erosion and patient adherence gapsLow−0.9LowLowLow
Total−6.5

Drivers contribute 51.3 Billion and restraints remove 6.5 Billion, a net 44.8 Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.

Growth in the global remote patient monitoring market comes from three measurable sources over 2026-2034: the market's own compounding at 11.3%, the share gained by faster-growing product type lines, and expansion in the regions taking a larger part of global revenue.

Analysis

Restraining Factors

Downside case: USD 59.4 billion by 2034, against USD 70.8 billion in the base case

Market Restraints

2
  • 01
    Downside case: USD 59.4 billion by 2034, against USD 70.8 billion in the base case

    The study's downside path assumes reimbursement rates are cut or tightened, alert fatigue and privacy compliance costs slow provider adoption, and device price erosion outpaces volume growth, and ends 2034 at USD 59.4 billion against the USD 70.8 billion base case, the same USD 26 billion base year, a slower forecast period.

  • 02
    The largest line is not the fastest

    With 24% of 2025 revenue (USD 6.24 billion) Vital Signs Monitors is where most of the market sits, and it grows at only 9.07% against the market's 11.3%. Revenue still reaches USD 14.16 billion by 2034 and share still falls to 20%: a drag on the average, not a decline.

Analysis

Market Opportunities

Where the forecast could be beaten

Market Opportunities

2
  • 01
    Where the forecast could be beaten

    A bull case of USD 80.6 billion by 2034, against USD 70.8 billion in the base case, turns on a single stated assumption: payers extend remote monitoring reimbursement to more conditions and countries, hospital-at-home programs scale quickly, and embedded cellular devices lift enrolment among older and rural patients. The USD 26 billion 2025 base is common to both.

  • 02
    Neurological Monitors is where share changes hands

    Neurological Monitors grows at 16.34% against 11.3% for the market, adding revenue from USD 1.04 billion in 2025 to USD 4.248 billion in 2034 and taking its share from 4% to 6%. It is the place on this axis where share changes hands at scale, so it is where an entrant can take position without displacing the incumbent in Vital Signs Monitors.

Analysis

Market Challenges

Concentration on the product type axis

Market Challenges

2
  • 01
    Concentration on the product type axis

    USD 6.24 billion of 2025 revenue sits in Vital Signs Monitors, 24% of the total, and it is still 20% at USD 14.16 billion nine years later. A market leaning this heavily on one product type line concentrates its exposure there, and a shift in demand for that line moves the total more than any other single change on the axis.

  • 02
    One country drives the leading region

    89.27% of the leading region is one country: the United States, at USD 9.4 billion against North America's USD 10.53 billion in 2025, and USD 22.1 billion by 2034. A regional number that depends this heavily on one country carries that country's specific conditions inside it, which a reader treating the region as diversified would miss.

Structure

Segmentation Analysis

10 axes

The market is divided by product type and by component, application, end user, connectivity technology, wearability, deployment mode, care model, patient age group and sales channel; ten axes in all. Each axis cuts the same total revenue along a different commercial dimension, so the splits are alternative views of one market, not additions to it.

There are eight lines on the product type axis, and all of them grow in revenue between 2025 and 2034. What separates them is share: three gain it, the rest give it up.

By Product Type · 8 segments

By Product Type

  • Largest Vital Signs Monitors · 24%
  • Fastest Neurological Monitors · 16.3%
  • Moves most Vital Signs Monitors · -4 pts
  • Order by 2034 changes
Segment2025Share2034ShareCAGR
Vital Signs Monitors$6.24B24%$14.16B20%-49.1%
Glucose Monitoring Devices$5.20B20%$15.58B22%+212.5%
Cardiac Monitoring Devices$5.72B22%$16.99B24%+212.4%
Respiratory Monitoring Devices$2.08B8%$5.66B8%11.3%
Multi-parameter Monitors$3.12B12%$7.08B10%-29.1%
Fetal and Neonatal Monitors$1.04B4%$2.83B4%11.3%
Neurological Monitors$1.04B4%$4.25B6%+216.3%
Weight and Body Composition Scales$1.56B6%$4.25B6%11.3%
Vital Signs Monitors 20%Glucose Monitoring Devices 22%Cardiac Monitoring Devices 24%Respiratory Monitoring Devices 8%Multi-parameter Monitors 10%Fetal and Neonatal Monitors 4%Neurological Monitors 6%Weight and Body Composition Scales 6%

2025 to 2034 revenue and share by line: Vital Signs Monitors USD 6.24 billion to USD 14.16 billion (24% to 20%), Cardiac Monitoring Devices USD 5.72 billion to USD 16.992 billion (22% to 24%), Glucose Monitoring Devices USD 5.2 billion to USD 15.576 billion (20% to 22%), Multi-parameter Monitors USD 3.12 billion to USD 7.08 billion (12% to 10%), Respiratory Monitoring Devices USD 2.08 billion to USD 5.664 billion (8% to 8%), Weight and Body Composition Scales USD 1.56 billion to USD 4.248 billion (6% to 6%), Fetal and Neonatal Monitors USD 1.04 billion to USD 2.832 billion (4% to 4%), Neurological Monitors USD 1.04 billion to USD 4.248 billion (4% to 6%). Vital Signs Monitors Led by Product type in 2025, with Neurological Monitors Growing Fastest Vital signs monitors lead because every care pathway needs them and they are the entry device in most programs. Neurological monitors grow fastest from a small base as wearable sensors for seizure and sleep tracking win clearances and clinicians accept home-collected data. Glucose and cardiac devices follow closely, helped by long-standing reimbursement and a clear link to avoided admissions. By 2034 the largest line is Cardiac Monitoring Devices and no longer Vital Signs Monitors, the one axis here where the order actually changes. This is the axis the estimation prices in full, year by year, and the one the regional chapters cut against.

By Component · 3 segments

Devices Held the Dominant Share of the Component Segment in 2025

  • Largest Devices · 52%
  • Fastest Software and Platforms · 14.9%
  • Moves most Devices · -10 pts
  • Order by 2034 unchanged
Segment2025Share2034ShareCAGR
Devices$13.52B52%$29.74B42%-109.2%
Software and Platforms$7.28B28%$25.49B36%+814.9%
Services$5.20B20%$15.58B22%+213%
Devices 42%Software and Platforms 36%Services 22%

Devices lead because every program starts with hardware shipped to the patient, and replacement cycles keep volumes steady. Software and platforms grow fastest as providers add analytics, alerting and electronic record integration and pay on a subscription basis. Services expand with enrolment support, clinical staffing and device logistics, though pricing pressure limits the pace. By 2034 Devices is still ahead, making this a shift in weight, not a change of leader.

By Application · 8 segments

By Application

  • Largest Cardiovascular Diseases · 30%
  • Fastest Neurological Disorders · 16%
  • Moves most Cardiovascular Diseases · -2 pts
  • Order by 2034 changes
Segment2025Share2034ShareCAGR
Cardiovascular Diseases$7.80B30%$19.82B28%-210.9%
Diabetes$6.24B24%$16.99B24%11.8%
Respiratory Diseases$3.12B12%$7.08B10%-29.5%
Neurological Disorders$1.30B5%$4.96B7%+216%
Cancer$1.56B6%$4.96B7%+113.7%
Maternal and Fetal Health$1.56B6%$4.25B6%11.8%
Post-acute and Post-operative Care$2.34B9%$7.79B11%+214.3%
Other Chronic Conditions$2.08B8%$4.96B7%-110.1%
Cardiovascular Diseases 28%Diabetes 24%Respiratory Diseases 10%Neurological Disorders 7%Cancer 7%Maternal and Fetal Health 6%Post-acute and Post-operative Care 11%Other Chronic Conditions 7%

2025 to 2034 revenue and share by line: Cardiovascular Diseases USD 7.8 billion to USD 19.824 billion (30% to 28%), Diabetes USD 6.24 billion to USD 16.992 billion (24% to 24%), Respiratory Diseases USD 3.12 billion to USD 7.08 billion (12% to 10%), Post-acute and Post-operative Care USD 2.34 billion to USD 7.788 billion (9% to 11%), Other Chronic Conditions USD 2.08 billion to USD 4.956 billion (8% to 7%), Cancer USD 1.56 billion to USD 4.956 billion (6% to 7%), Maternal and Fetal Health USD 1.56 billion to USD 4.248 billion (6% to 6%), Neurological Disorders USD 1.3 billion to USD 4.956 billion (5% to 7%). Cardiovascular Diseases Held the Dominant Share of the Application Segment in 2025 Cardiovascular disease leads because heart failure and arrhythmia have the largest monitored populations and the most established clinical protocols. Neurological disorders grow fastest from a small base as wearable sensing for epilepsy, sleep and movement disorders moves into routine care. Diabetes remains large through continuous glucose monitoring, while post-acute care gains from early discharge programs. Cardiovascular Diseases remains the largest line through 2034, so the axis changes in proportion, not in order.

By End User · 6 segments

Home Care Settings Both Leads the End user Axis and Grows Fastest on It

  • Largest Home Care Settings · 34%
  • Fastest Home Care Settings · 14.4%
  • Moves most Home Care Settings · +8 pts
  • Order by 2034 changes
Segment2025Share2034ShareCAGR
Home Care Settings$8.84B34%$29.74B42%+814.4%
Hospitals and Clinics$7.80B30%$16.99B24%-69%
Ambulatory Care Centers$2.34B9%$5.66B8%-110.3%
Assisted Living and Long-term Care Facilities$3.12B12%$7.08B10%-29.5%
Rehabilitation Centers$1.56B6%$3.54B5%-19.5%
Payers and Care Management Organizations$2.34B9%$7.79B11%+214.3%
Home Care Settings 42%Hospitals and Clinics 24%Ambulatory Care Centers 8%Assisted Living and Long-term Care Facilities 10%Rehabilitation Centers 5%Payers and Care Management Organizations 11%

Home care leads and grows fastest because reimbursement now follows the patient out of the hospital and consumer-grade connected devices are accepted by clinicians. Hospitals stay large through discharge programs and chronic clinics run by their own staff, but grow slowest as work moves to the home. Payers and care management organisations expand as they fund programs to cut admissions. The order does not change: Home Care Settings is still largest in 2034, and what moves is how much it holds.

By Connectivity Technology · 5 segments

Scale in Bluetooth and Growth in Cellular Define the Connectivity technology Axis

  • Largest Bluetooth · 38%
  • Fastest Cellular · 16.5%
  • Moves most Cellular · +10 pts
  • Order by 2034 unchanged
Segment2025Share2034ShareCAGR
Bluetooth$9.88B38%$24.07B34%-410.4%
Wi-Fi$4.68B18%$9.91B14%-48.7%
Cellular$5.72B22%$22.66B32%+1016.5%
Wired and Hub-based$3.64B14%$7.08B10%-47.7%
Other Wireless Protocols$2.08B8%$7.08B10%+214.6%
Bluetooth 34%Wi-Fi 14%Cellular 32%Wired and Hub-based 10%Other Wireless Protocols 10%

Bluetooth leads because most consumer-grade and clinical peripherals pair with a phone or gateway at low cost and low power. Cellular grows fastest as suppliers ship devices with built-in connections that work without a patient's phone or home broadband, which raises enrolment among older and rural patients. Wired and hub-based links lose share as embedded cellular and low-power wide-area options replace them. The order does not change: Bluetooth is still largest in 2034, and what moves is how much it holds.

By Wearability · 4 segments

Scale in Tabletop and Bedside and Growth in Wearable Define the Wearability Axis

  • Largest Tabletop and Bedside · 38%
  • Fastest Wearable · 15.8%
  • Moves most Wearable · +12 pts
  • Order by 2034 changes
Segment2025Share2034ShareCAGR
Wearable$8.32B32%$31.15B44%+1215.8%
Handheld$5.72B22%$12.74B18%-49.3%
Tabletop and Bedside$9.88B38%$19.82B28%-108.1%
Implantable and Ingestible$2.08B8%$7.08B10%+214.6%
Wearable 44%Handheld 18%Tabletop and Bedside 28%Implantable and Ingestible 10%

Tabletop and bedside units lead because they cover the established base of blood pressure, weight and oximetry equipment already placed in homes and wards. Wearables grow fastest as patches and watches offer continuous data, longer battery life and clinical clearances, and as patients keep them on for weeks. Handheld devices grow modestly, with smartphone-linked tools taking part of their use. Leadership changes hands: Wearable is the largest line by 2034, not Tabletop and Bedside.

By Deployment Mode · 3 segments

Scale in Cloud-based and Growth in Hybrid Define the Deployment mode Axis

  • Largest Cloud-based · 56%
  • Fastest Hybrid · 14.1%
  • Moves most On-premise · -10 pts
  • Order by 2034 changes
Segment2025Share2034ShareCAGR
Cloud-based$14.56B56%$43.90B62%+613.1%
On-premise$6.24B24%$9.91B14%-105.3%
Hybrid$5.20B20%$16.99B24%+414.1%
Cloud-based 62%On-premise 14%Hybrid 24%

Cloud-based deployment leads and grows quickly because providers avoid running servers, vendors push updates to every site, and data from home devices already arrives over the internet. Hybrid setups grow as health systems keep sensitive records on site while using cloud analytics. On-premise installations lose share as security assurances improve and IT teams shrink. The fastest line is Hybrid, which is why the split shifts toward it over the period. The order does not change: Cloud-based is still largest in 2034, and what moves is how much it holds.

By Care Model · 5 segments

Hospital-at-home Outpaces the Axis While Chronic Care Management Holds the Largest Share

  • Largest Chronic Care Management · 36%
  • Fastest Hospital-at-home · 17.8%
  • Moves most Hospital-at-home · +6 pts
  • Order by 2034 changes
Segment2025Share2034ShareCAGR
Real-time Monitoring$8.84B34%$22.66B32%-211%
Store-and-forward Monitoring$2.08B8%$4.25B6%-28.3%
Hospital-at-home$2.60B10%$11.33B16%+617.8%
Chronic Care Management$9.36B36%$24.07B34%-211.1%
Principal Care Management$3.12B12%$8.50B12%11.8%
Real-time Monitoring 32%Store-and-forward Monitoring 6%Hospital-at-home 16%Chronic Care Management 34%Principal Care Management 12%

Chronic care management leads because it fits the recurring monthly billing structure that supports long-running enrolments for conditions such as hypertension and diabetes. Hospital-at-home grows fastest as health systems and payers fund acute-level care in the patient's residence, and that care needs continuous monitoring kits. Store-and-forward monitoring grows slowest as live data becomes the norm. Chronic Care Management remains the largest line through 2034, so the axis changes in proportion, not in order.

By Patient Age Group · 4 segments

Neonatal Outpaces the Axis While Geriatric Holds the Largest Share

  • Largest Geriatric · 48%
  • Fastest Neonatal · 14.6%
  • Moves most Adult · -3 pts
  • Order by 2034 unchanged
Segment2025Share2034ShareCAGR
Geriatric$12.48B48%$35.40B50%+212.3%
Adult$10.40B40%$26.20B37%-310.8%
Pediatric$2.08B8%$5.66B8%11.8%
Neonatal$1.04B4%$3.54B5%+114.6%
Geriatric 50%Adult 37%Pediatric 8%Neonatal 5%

Geriatric patients lead because the prevalence of heart failure, hypertension, diabetes and chronic lung disease rises with age and older adults are the main target of home-based programs. Neonatal monitoring grows fastest from a very small base as home-going monitors for premature infants and connected neonatal units spread. Adult use follows at a steady pace, tied to workplace and insurer programs. The order does not change: Geriatric is still largest in 2034, and what moves is how much it holds.

By Sales Channel · 5 segments

Direct to Providers Led by Sales channel in 2025, with Payer-sponsored Programs Growing Fastest

  • Largest Direct to Providers · 38%
  • Fastest Payer-sponsored Programs · 15.8%
  • Moves most Distributors and Wholesalers · -6 pts
  • Order by 2034 changes
Segment2025Share2034ShareCAGR
Direct to Providers$9.88B38%$24.07B34%-410.4%
Distributors and Wholesalers$6.24B24%$12.74B18%-68.3%
Retail and Pharmacies$2.60B10%$7.08B10%11.8%
Online and E-commerce$3.12B12%$11.33B16%+415.4%
Payer-sponsored Programs$4.16B16%$15.58B22%+615.8%
Direct to Providers 34%Distributors and Wholesalers 18%Retail and Pharmacies 10%Online and E-commerce 16%Payer-sponsored Programs 22%

Direct sales to providers lead because hospitals and health systems buy bundled kits, software and services under contracts negotiated with the supplier. Payer-sponsored programs grow fastest as insurers and employers fund devices for members and pay per enrolled patient. Online sales grow through direct purchases of connected scales, glucometers and blood pressure cuffs, while distributors lose share as large suppliers sell direct. Direct to Providers remains the largest line through 2034, so the axis changes in proportion, not in order.

Analysis

Regional Insights

Regional Revenue Share

Base year 2025
41%
North America
Leading region
41%North America

Share of global revenue in the base year.

North America
Europe
Asia Pacific
Latin America
Middle East and Africa

Only the leading region's share is published outside the report; pins mark the region, not a specific country.

Leading Region
North America leads with 41% of global revenue through 2034

North America Market Analysis

The largest region covered — 5.5 points of share move elsewhere by 2034, while revenue still grows 2.5×.

  • Rank 1 of 5
  • 2025 share 41%
  • By 2034 35.5%
  • Revenue $23.78B → $59.99B

on the way to USD 24.85 billion by 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.

, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

The product type mix reported at global level applies here, with Vital Signs Monitors the largest line at 24% of 2025 revenue and Neurological Monitors the fastest-growing at 16.34%. Per-axis and per-country detail for North America sits in the full report.

United States

Sets the pace for North America at 89.3% of it, growing 2.4×.

  • In region 1 of 2
  • Of region 89.3%
  • Of global 36.1%
  • Revenue $9.40B → $22.10B

USD 9.4 billion of North America's 2025 revenue is generated in the United States, the region's largest market, reaching USD 22.1 billion by 2034. At 89.27% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. Regional revenue of USD 10.53 billion in 2025 and USD 24.85 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in the United States follows the product type mix reported at global level: Vital Signs Monitors is the largest line at 24% of 2025 revenue, moving to 20% by 2034, while Neurological Monitors grows fastest at 16.34% and takes its share from 4% to 6%. Because the country carries 89.27% of North America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Per-product type revenue for the United States appears on its own in the full report.

In the United States, remote patient monitoring devices fall under the Food and Drug Administration, which classifies them as medical devices by risk. Most monitors that measure vital signs reach the market through premarket notification, with higher-risk products needing premarket approval or a De Novo request. Suppliers must register their establishment, list their devices, follow the quality system regulation and report adverse events. Labelling must carry the intended use and instructions for the clinician and the patient. Software that analyses readings can fall under the agency's software as a medical device guidance. Separately, health data handling is governed by the federal health privacy law, and reimbursement is set by the Centers for Medicare and Medicaid Services.

Koninklijke Philips N.V., Medtronic plc, GE HealthCare Technologies Inc., Masimo Corporation, Abbott Laboratories, Dexcom, Inc., OMRON Healthcare, Inc., iRhythm Technologies, Inc., Boston Scientific Corporation, Siemens Healthineers AG, Baxter International Inc., BioTelemetry, Inc., Biotricity Inc., Teladoc Health, Inc., Vivify Health, Inc., Resideo Technologies, Inc., VitalConnect, Inc., VivaLNK, Inc., Oracle Corporation, Health Recovery Solutions, Inc., Best Buy Health, Inc., Cadence (Cadence Health), Inc., BioIntelliSense, Inc., Withings SA, Tunstall Healthcare Group Ltd., Medtronic Care Management Services, A&D Company, Limited, Insulet Corporation, ResMed Inc. and CareClix (Dignity Health Global Education) are the suppliers covered in the United States. Volume sits in Vital Signs Monitors at 24% of 2025 revenue; movement sits in Neurological Monitors at 16.34% growth. Country-level shares and positioning per company sit in the full report.

Canada

2nd-largest in North America, growing 2.4×.

  • In region 2 of 2
  • Of region 9%
  • Of global 3.6%
  • Revenue $0.95B → $2.25B

Within North America, Canada accounts for 9.02% of regional revenue and 3.65% of the global total, worth USD 0.95 billion in 2025 and USD 2.25 billion by 2034.

Europe Market Analysis

The 2nd-largest region covered — 1.5 points of share move elsewhere by 2034, while revenue still grows 2.7×.

  • Rank 2 of 5
  • 2025 share 24%
  • By 2034 22.5%
  • Revenue $13.92B → $38.03B

and reaches USD 16.35 billion by 2034. That makes it the second-largest region covered, in 2025 and again in 2034.

, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

The product type mix reported at global level applies here, with Vital Signs Monitors the largest line at 24% of 2025 revenue and Neurological Monitors the fastest-growing at 16.34%. Per-axis and per-country detail for Europe sits in the full report.

Germany

The largest market in Europe, growing 2.6×.

  • In region 1 of 3
  • Of region 24.8%
  • Of global 6%
  • Revenue $1.55B → $4B

24.84% of Europe's base-year revenue comes from Germany; USD 1.55 billion, rising to USD 4 billion by 2034. Its 24.84% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Set against USD 6.24 billion and USD 16.35 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

Germany buys along the same lines as the market globally; Vital Signs Monitors first at 24% of 2025 revenue and 20% in 2034, Neurological Monitors fastest at 16.34% on a share moving from 4% to 6%. With 24.84% of Europe concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Revenue by product type for Germany is reported separately in the full report.

Germany applies the European Union Medical Device Regulation, with national oversight by the Federal Institute for Drugs and Medical Devices. A monitoring device is classified by risk and, above the lowest class, must be assessed by a notified body before it carries the CE mark. Suppliers need a quality management system, technical documentation, clinical evaluation and post-market surveillance, and non-European makers must appoint an authorised representative. Labelling follows harmonised standards for safety, usability and software lifecycle. Data collected from patients falls under the General Data Protection Regulation. Certain digital health applications can also be listed for statutory insurance reimbursement after a review by the federal institute.

In Germany the field is Koninklijke Philips N.V., Medtronic plc, GE HealthCare Technologies Inc., Masimo Corporation, Abbott Laboratories, Dexcom, Inc., OMRON Healthcare, Inc., iRhythm Technologies, Inc., Boston Scientific Corporation, Siemens Healthineers AG, Baxter International Inc., BioTelemetry, Inc., Biotricity Inc., Teladoc Health, Inc., Vivify Health, Inc., Resideo Technologies, Inc., VitalConnect, Inc., VivaLNK, Inc., Oracle Corporation, Health Recovery Solutions, Inc., Best Buy Health, Inc., Cadence (Cadence Health), Inc., BioIntelliSense, Inc., Withings SA, Tunstall Healthcare Group Ltd., Medtronic Care Management Services, A&D Company, Limited, Insulet Corporation, ResMed Inc. and CareClix (Dignity Health Global Education). Volume sits in Vital Signs Monitors at 24% of 2025 revenue; movement sits in Neurological Monitors at 16.34% growth. The commercial size of that position is USD 6.24 billion in 2025, moving to USD 16.35 billion by 2034 across the forecast period.

United Kingdom

2nd-largest in Europe, growing 2.5×.

  • In region 2 of 3
  • Of region 20.8%
  • Of global 5%
  • Revenue $1.30B → $3.20B

5% of global revenue is generated in the United Kingdom; USD 1.3 billion in 2025, reaching USD 3.2 billion in 2034, and 20.83% of Europe.

France

3rd-largest in Europe, growing 2.5×.

  • In region 3 of 3
  • Of region 15.2%
  • Of global 3.6%
  • Revenue $0.95B → $2.40B

Within Europe, France accounts for 15.22% of regional revenue and 3.65% of the global total, worth USD 0.95 billion in 2025 and USD 2.4 billion by 2034.

Asia Pacific Market Analysis

The 3rd-largest region covered, and the one gaining the most — it picks up 8 points of share by 2034, while revenue still grows 3.9×.

  • Rank 3 of 5
  • 2025 share 23%
  • By 2034 31%
  • Revenue $13.34B → $52.39B

rising to USD 21.1 billion in 2034. Among the five regions it ranks third by revenue in both years.

, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

Within the region the product type split tracks the global one; 24% of 2025 revenue in Vital Signs Monitors, fastest growth of 16.34% in Neurological Monitors. Asia Pacific is reported axis by axis and country by country in the full study.

China

The largest market in Asia Pacific, growing 3.6×.

  • In region 1 of 3
  • Of region 34.4%
  • Of global 8.1%
  • Revenue $2.10B → $7.60B

China is the largest market within Asia Pacific, generating USD 2.1 billion in 2025 and projected to reach USD 7.6 billion by 2034. 34.37% of the region in the base year makes it the largest market here without making it the region. Regional revenue of USD 6.11 billion in 2025 and USD 21.1 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in China follows the product type mix reported at global level: Vital Signs Monitors is the largest line at 24% of 2025 revenue, moving to 20% by 2034, while Neurological Monitors grows fastest at 16.34% and takes its share from 4% to 6%. With 34.37% of Asia Pacific concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Revenue by product type for China is reported separately in the full report.

In China, the National Medical Products Administration regulates remote patient monitoring equipment as a medical device, classified into risk categories under the device supervision regulations. Lower-risk products are filed with the authorities, while higher-risk ones need registration backed by testing at an accredited institute and clinical evaluation. Foreign suppliers must appoint a local legal agent and register through that agent. Products must conform to mandatory national and industry standards, and labelling and instructions must appear in Chinese. Software and networked devices also face rules on cybersecurity, personal information protection and the export or storage of health data inside the country.

In China the field is Koninklijke Philips N.V., Medtronic plc, GE HealthCare Technologies Inc., Masimo Corporation, Abbott Laboratories, Dexcom, Inc., OMRON Healthcare, Inc., iRhythm Technologies, Inc., Boston Scientific Corporation, Siemens Healthineers AG, Baxter International Inc., BioTelemetry, Inc., Biotricity Inc., Teladoc Health, Inc., Vivify Health, Inc., Resideo Technologies, Inc., VitalConnect, Inc., VivaLNK, Inc., Oracle Corporation, Health Recovery Solutions, Inc., Best Buy Health, Inc., Cadence (Cadence Health), Inc., BioIntelliSense, Inc., Withings SA, Tunstall Healthcare Group Ltd., Medtronic Care Management Services, A&D Company, Limited, Insulet Corporation, ResMed Inc. and CareClix (Dignity Health Global Education). Volume sits in Vital Signs Monitors at 24% of 2025 revenue; movement sits in Neurological Monitors at 16.34% growth. A supplier weighted toward Asia Pacific is competing over a base of USD 6.11 billion in 2025, reaching USD 21.1 billion by 2034 on the trajectory this study models.

Japan

2nd-largest in Asia Pacific, growing 2.3×.

  • In region 2 of 3
  • Of region 24.6%
  • Of global 5.8%
  • Revenue $1.50B → $3.40B

5.77% of global revenue is generated in Japan; USD 1.5 billion in 2025, reaching USD 3.4 billion in 2034, and 24.55% of Asia Pacific.

India

3rd-largest in Asia Pacific, growing 4.7×.

  • In region 3 of 3
  • Of region 9%
  • Of global 2.1%
  • Revenue $0.55B → $2.60B

Within Asia Pacific, India accounts for 9% of regional revenue and 2.12% of the global total, worth USD 0.55 billion in 2025 and USD 2.6 billion by 2034.

Latin America Market Analysis

The 5th-largest region covered, holding its share flat through 2034, while revenue still grows 2.9×.

  • Rank 5 of 5
  • 2025 share 5.5%
  • By 2034 5.5%
  • Revenue $3.19B → $9.30B

on the way to USD 4.25 billion by 2034. It is a marginal region on this axis, fourth by revenue throughout the period.

, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Segment composition follows the global pattern: Vital Signs Monitors largest at 24% of 2025 revenue, Neurological Monitors fastest at 16.34%. The full report breaks Latin America out along every axis and by country.

Brazil

The largest market in Latin America, growing 2.8×.

  • In region 1 of 2
  • Of region 38.5%
  • Of global 2.3%
  • Revenue $0.60B → $1.70B

Brazil is the largest market within Latin America, generating USD 0.6 billion in 2025 and projected to reach USD 1.7 billion by 2034. At 38.46% of the region in 2025 it leads, but a majority of Latin America's revenue is generated in other markets. The region itself runs USD 1.56 billion to USD 4.25 billion over the same period, and this is the market carrying the country-level detail in the full report.

Demand in Brazil follows the product type mix reported at global level: Vital Signs Monitors is the largest line at 24% of 2025 revenue, moving to 20% by 2034, while Neurological Monitors grows fastest at 16.34% and takes its share from 4% to 6%. Since 38.46% of Latin America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Per-product type revenue for Brazil appears on its own in the full report.

Brazil's health surveillance agency, ANVISA, regulates remote patient monitoring devices as medical products and assigns them to a risk class. Lower-risk classes follow a notification route, while higher-risk products need full registration. Foreign manufacturers must work through a local registration holder and generally demonstrate compliance with good manufacturing practices, often through an inspection or a recognised audit scheme. Many electrical devices must also be certified by a national conformity body under INMETRO rules. Labels and instructions must be in Portuguese and carry the registration identifier. Patient information is subject to the national general data protection law, which affects cloud-based monitoring platforms.

Competition in Brazil runs between the suppliers this study tracks: Koninklijke Philips N.V., Medtronic plc, GE HealthCare Technologies Inc., Masimo Corporation, Abbott Laboratories, Dexcom, Inc., OMRON Healthcare, Inc., iRhythm Technologies, Inc., Boston Scientific Corporation, Siemens Healthineers AG, Baxter International Inc., BioTelemetry, Inc., Biotricity Inc., Teladoc Health, Inc., Vivify Health, Inc., Resideo Technologies, Inc., VitalConnect, Inc., VivaLNK, Inc., Oracle Corporation, Health Recovery Solutions, Inc., Best Buy Health, Inc., Cadence (Cadence Health), Inc., BioIntelliSense, Inc., Withings SA, Tunstall Healthcare Group Ltd., Medtronic Care Management Services, A&D Company, Limited, Insulet Corporation, ResMed Inc. and CareClix (Dignity Health Global Education). Vital Signs Monitors, at 24% of 2025 revenue, is where the volume sits, and Neurological Monitors, growing at 16.34%, is where position changes hands over the forecast period. A supplier weighted toward Latin America is competing over a base of USD 1.56 billion in 2025, reaching USD 4.25 billion by 2034 on the trajectory this study models.

Mexico

2nd-largest in Latin America, growing 2.9×.

  • In region 2 of 2
  • Of region 24.4%
  • Of global 1.5%
  • Revenue $0.38B → $1.10B

1.46% of global revenue is generated in Mexico; USD 0.38 billion in 2025, reaching USD 1.1 billion in 2034, and 24.36% of Latin America.

Middle East and Africa Market Analysis

The 4th-largest region covered — 1 point of share move elsewhere by 2034, while revenue still grows 2.5×.

  • Rank 4 of 5
  • 2025 share 6.5%
  • By 2034 5.5%
  • Revenue $3.77B → $9.29B

rising to USD 4.25 billion in 2034. It is a marginal region on this axis, fifth by revenue throughout the period.

, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

The product type mix reported at global level applies here, with Vital Signs Monitors the largest line at 24% of 2025 revenue and Neurological Monitors the fastest-growing at 16.34%. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.

Saudi Arabia

The largest market in Middle East and Africa, growing 2.8×.

  • In region 1 of 3
  • Of region 19.2%
  • Of global 1.1%
  • Revenue $0.30B → $0.85B

Saudi Arabia is the largest market within Middle East and Africa, generating USD 0.3 billion in 2025 and projected to reach USD 0.85 billion by 2034. 19.23% of the region in the base year makes it the largest market here without making it the region. The region itself runs USD 1.56 billion to USD 4.25 billion over the same period, and this is the market carrying the country-level detail in the full report.

Demand in Saudi Arabia follows the product type mix reported at global level: Vital Signs Monitors is the largest line at 24% of 2025 revenue, moving to 20% by 2034, while Neurological Monitors grows fastest at 16.34% and takes its share from 4% to 6%. Since 19.23% of Middle East and Africa's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Per-product type revenue for Saudi Arabia appears on its own in the full report.

In Saudi Arabia, the Saudi Food and Drug Authority regulates remote patient monitoring devices under its medical device interim regulation. Devices are classified by risk, and suppliers must obtain a marketing authorisation, usually supported by evidence of approval in a reference market and a conformity assessment. Overseas manufacturers must appoint a local authorised representative who holds the licence and handles complaints and recalls. Establishments are licensed, and post-market vigilance reporting is required. Labelling must include Arabic information alongside English, and devices must meet applicable international safety standards. Health data handling is governed by the national personal data protection law and by health-sector rules on storing data within the kingdom.

In Saudi Arabia the field is Koninklijke Philips N.V., Medtronic plc, GE HealthCare Technologies Inc., Masimo Corporation, Abbott Laboratories, Dexcom, Inc., OMRON Healthcare, Inc., iRhythm Technologies, Inc., Boston Scientific Corporation, Siemens Healthineers AG, Baxter International Inc., BioTelemetry, Inc., Biotricity Inc., Teladoc Health, Inc., Vivify Health, Inc., Resideo Technologies, Inc., VitalConnect, Inc., VivaLNK, Inc., Oracle Corporation, Health Recovery Solutions, Inc., Best Buy Health, Inc., Cadence (Cadence Health), Inc., BioIntelliSense, Inc., Withings SA, Tunstall Healthcare Group Ltd., Medtronic Care Management Services, A&D Company, Limited, Insulet Corporation, ResMed Inc. and CareClix (Dignity Health Global Education). Vital Signs Monitors, at 24% of 2025 revenue, is where the volume sits, and Neurological Monitors, growing at 16.34%, is where position changes hands over the forecast period. A supplier weighted toward Middle East and Africa is competing over a base of USD 1.56 billion in 2025, reaching USD 4.25 billion by 2034 on the trajectory this study models.

United Arab Emirates

2nd-largest in Middle East and Africa, growing 2.7×.

  • In region 2 of 3
  • Of region 14.1%
  • Of global 0.8%
  • Revenue $0.22B → $0.60B

Within Middle East and Africa, the United Arab Emirates accounts for 14.1% of regional revenue and 0.85% of the global total, worth USD 0.22 billion in 2025 and USD 0.6 billion by 2034.

South Africa

3rd-largest in Middle East and Africa, growing 2.5×.

  • In region 3 of 3
  • Of region 12.8%
  • Of global 0.8%
  • Revenue $0.20B → $0.50B

0.77% of global revenue is generated in South Africa; USD 0.2 billion in 2025, reaching USD 0.5 billion in 2034, and 12.82% of Middle East and Africa.

Download a free sample to see the full data tables and segment-level detail behind this analysis.

Analysis

Report Coverage

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by product type, component, application, end user, connectivity technology, wearability, deployment mode, care model, patient age group, sales channel, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.

Competition

Competitive Landscape

Scale in Vital Signs Monitors and Growth in Neurological Monitors Set the Terms of Competition

Suppliers in scope: Koninklijke Philips N.V., Medtronic plc, GE HealthCare Technologies Inc., Masimo Corporation, Abbott Laboratories, Dexcom, Inc., OMRON Healthcare, Inc., iRhythm Technologies, Inc., Boston Scientific Corporation, Siemens Healthineers AG, Baxter International Inc., BioTelemetry, Inc., Biotricity Inc., Teladoc Health, Inc., Vivify Health, Inc., Resideo Technologies, Inc., VitalConnect, Inc., VivaLNK, Inc., Oracle Corporation, Health Recovery Solutions, Inc., Best Buy Health, Inc., Cadence (Cadence Health), Inc., BioIntelliSense, Inc., Withings SA, Tunstall Healthcare Group Ltd., Medtronic Care Management Services, A&D Company, Limited, Insulet Corporation, ResMed Inc. and CareClix (Dignity Health Global Education).

The competitive line that matters is the product type one, not the geographic one. Volume sits in Vital Signs Monitors, USD 6.24 billion and 24% of 2025 revenue, 20% by 2034, which is also where an incumbent is hardest to dislodge. Share moves in Neurological Monitors, growing 16.34% against 9.07% for Multi-parameter Monitors. Those are different problems, and a supplier strong in one is not thereby strong in the other; that is what sustains a field this size in a USD 26 billion market.

Suppliers separate on regulatory clearance across many device types and regions, the ability to bundle devices, connectivity and software into one contract, and integration with the electronic health record systems that clinicians already use. The largest players hold clinical evidence, hospital relationships, manufacturing scale and the reimbursement know-how that helps customers bill successfully. Smaller and regional suppliers compete on single-condition depth, lower prices, local language support and fast integration with national health systems, or on consumer brands that reach patients through retail and online channels.

Per-company profiles, financials, share and development history are in the full report and not here.

List of Key Remote Patient Monitoring Market Companies Profiled

30 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.

  • Koninklijke Philips N.V.(Netherlands)
  • Medtronic plc(Ireland)
  • GE HealthCare Technologies Inc.(United States)
  • Masimo Corporation(United States)
  • Abbott Laboratories(United States)
  • Dexcom, Inc.(United States)
  • OMRON Healthcare, Inc.(Japan)
  • iRhythm Technologies, Inc.(United States)
  • Boston Scientific Corporation(United States)
  • Siemens Healthineers AG(Germany)
  • Baxter International Inc.(United States)
  • BioTelemetry, Inc.(United States)
  • Biotricity Inc.(United States)
  • Teladoc Health, Inc.(United States)
  • Vivify Health, Inc.(United States)
  • Resideo Technologies, Inc.(United States)
  • VitalConnect, Inc.(United States)
  • VivaLNK, Inc.(United States)
  • Oracle Corporation(United States)
  • Health Recovery Solutions, Inc.(United States)
  • Best Buy Health, Inc.(United States)
  • Cadence (Cadence Health), Inc.(United States)
  • BioIntelliSense, Inc.(United States)
  • Withings SA(France)
  • Tunstall Healthcare Group Ltd.(United Kingdom)
  • Medtronic Care Management Services(United States)
  • A&D Company, Limited(Japan)
  • Insulet Corporation(United States)
  • ResMed Inc.(United States)
  • CareClix (Dignity Health Global Education)(United States)
Coverage

Geographic Coverage

5 regions · 30 markets

Every market below is broken out separately in the report.

North America

3
USCanadaMexico

Europe

8
GermanyFranceItalySpainUKNordic CountriesBenelux UnionRest of Europe

Asia Pacific

12
IndiaAustraliaChinaChina (Taiwan)JapanSouth KoreaSoutheast AsiaIndonesiaThailandMalaysiaSingaporeRest of Asia Pacific

Latin America

3
BrazilArgentinaRest of Latin America

Middle East and Africa

4
GCCEgyptSouth AfricaRest of the Middle East & Africa
At a glance

Key Insights

5
Regions covered
Including North America, Europe, Asia Pacific.
30
Companies profiled
Leading companies active in this market.
2025
Base year
Verified base-year data underpins every estimate.
2020–2034
Study period
Historical actuals plus the full forecast horizon.
Parameters

Report Scope

Study parameters & segmentation

This study covers market size and forecasts over the 2020–2034 period, segmentation across 10 axes (Product Type, Component, Application, End User, Connectivity Technology, Wearability, Deployment Mode, Care Model, Patient Age Group, Sales Channel), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 30 key companies, and the research methodology behind every estimate.

Study period
2020–2034
Base year
2025
Estimated year
2026
Historical period
2020-2024
Forecast period
2026-2034
Growth rate
11.3% CAGR
Unit
USD Billion

Segmentation

10 axes + region
By Product Type
Vital Signs MonitorsGlucose Monitoring DevicesCardiac Monitoring DevicesRespiratory Monitoring DevicesMulti-parameter MonitorsFetal and Neonatal MonitorsNeurological MonitorsWeight and Body Composition Scales
By Component
DevicesSoftware and PlatformsServices
By Application
Cardiovascular DiseasesDiabetesRespiratory DiseasesNeurological DisordersCancerMaternal and Fetal HealthPost-acute and Post-operative CareOther Chronic Conditions
By End User
Home Care SettingsHospitals and ClinicsAmbulatory Care CentersAssisted Living and Long-term Care FacilitiesRehabilitation CentersPayers and Care Management Organizations
By Connectivity Technology
BluetoothWi-FiCellularWired and Hub-basedOther Wireless Protocols
By Wearability
WearableHandheldTabletop and BedsideImplantable and Ingestible
By Deployment Mode
Cloud-basedOn-premiseHybrid
By Care Model
Real-time MonitoringStore-and-forward MonitoringHospital-at-homeChronic Care ManagementPrincipal Care Management
By Patient Age Group
GeriatricAdultPediatricNeonatal
By Sales Channel
Direct to ProvidersDistributors and WholesalersRetail and PharmaciesOnline and E-commercePayer-sponsored Programs
By Geography
North America: US, Canada, Mexico
Europe: Germany, France, Italy, Spain, UK, Nordic Countries, Benelux Union, Rest of Europe
Asia Pacific: India, Australia, China, China (Taiwan), Japan, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Asia Pacific
Latin America: Brazil, Argentina, Rest of Latin America
Middle East and Africa: GCC, Egypt, South Africa, Rest of the Middle East & Africa
Backed by primary research into key growth drivers, competitive dynamics, and regional demand shifts. Full analysis is available in the sample report.
Scope

Questions This Report Answers

6 questions
01

What is the market size and growth rate, globally and by region?

02

How is the market segmented, and which segments lead?

03

Which regions and countries are covered, and how do they compare?

04

What are the key drivers, restraints, opportunities and challenges?

05

Who are the leading companies operating in this market?

06

What trends are expected to shape the market through the forecast period?

Questions

Frequently Asked Questions

01What is the Remote Patient Monitoring Market projected to reach?

USD 70.8 Billion by 2034, CAGR 11.3%

02What years does this report cover?

Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.

03Which regions are covered?

North America, Europe, Asia Pacific, Latin America, Middle East and Africa.

04Which region accounted for the largest market share?

North America leads with 41% of global revenue through 2034.

05Which segment leads the market?

Vital Signs Monitors is the largest line by product type, at 24% of revenue in 2025.

06Who are the key companies profiled?

Koninklijke Philips N.V., Medtronic plc, GE HealthCare Technologies Inc., Masimo Corporation, Abbott Laboratories, Dexcom, Inc., OMRON Healthcare, Inc., iRhythm Technologies, Inc., Boston Scientific Corporation, Siemens Healthineers AG, Baxter International Inc., BioTelemetry, Inc., Biotricity Inc., Teladoc Health, Inc., Vivify Health, Inc., Resideo Technologies, Inc., VitalConnect, Inc., VivaLNK, Inc., Oracle Corporation, Health Recovery Solutions, Inc., Best Buy Health, Inc., Cadence (Cadence Health), Inc., BioIntelliSense, Inc., Withings SA, Tunstall Healthcare Group Ltd., Medtronic Care Management Services, A&D Company, Limited, Insulet Corporation, ResMed Inc., CareClix (Dignity Health Global Education). Full profiles are part of the paid report.

07Can the segmentation be customized?

Yes. Custom data cuts by geography, segment, or competitor set are available on request.

425+
Dedicated research analysts
1,200+
Reports published
Why CDI

Why choose CDI

Data triangulated across primary and secondary sources
Complimentary analyst call included with every purchase
Custom data cuts and post-purchase support available

Need this report shaped around your question?

The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.

Most licences include 30–60 hours of customization at no extra cost. See what each licence includes

Request customization

Additional Companies

Add competitors, suppliers or the peer set you benchmark against to the companies already covered.

Deeper Competitive View

Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.

Extra Segment Splits

Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.

Application Focus

Narrow the analysis to the specific use cases and end users your team actually sells into.

Different Time Frame

Move the base year, or widen the historical and forecast windows the study is built on.

Country-Level Detail

Go below region level into the individual countries that matter to you, rather than the standard geography split.